News

U nder the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical ...
The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s work, current ...
The Hershey Company (NYSE:HSY) is one of the 10 best defensive stocks to buy in a volatile market. On June 30, the company ...
Makary and Center for Biologics Evaluation and Research Director Vinay Prasad unveiled a new framework in the New England Journal of Medicine on May 20 requiring a stronger evidence base for boosters ...
H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health ...
FDA Commissioner Marty Makary’s pledge to reexamine the safety of medication abortion isn’t just pointless — it’s dangerous.
The FDA signed off on KalVista Pharmaceuticals' emergency treatment for swelling attacks associated with a rare, genetic ...
Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...
Medical associations representing hundreds of thousands of doctors, medical professionals and scientists in the United States ...
The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.
The health secretary has used peer pressure to persuade food makers to nix synthetic dyes. The candy industry is holding out, ...
The lawsuit argues that the HHS secretary’s withdrawal of public vaccine advice reduces access to vaccines for some people.